- Home
- TSVT vs SLRN Comparison
TSVT vs SLRN Comparison
Compare TSVT & SLRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- SLRN
- Stock Information
- Founded
- TSVT 2021
- SLRN 2020
- Country
- TSVT United States
- SLRN United States
- Employees
- TSVT N/A
- SLRN N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- SLRN Biotechnology: Pharmaceutical Preparations
- Sector
- TSVT Health Care
- SLRN Health Care
- Exchange
- TSVT Nasdaq
- SLRN Nasdaq
- Market Cap
- TSVT 258.9M
- SLRN 224.6M
- IPO Year
- TSVT N/A
- SLRN 2023
- Fundamental
- Price
- TSVT $4.99
- SLRN $2.36
- Analyst Decision
- TSVT Buy
- SLRN Hold
- Analyst Count
- TSVT 4
- SLRN 5
- Target Price
- TSVT $6.50
- SLRN $9.60
- AVG Volume (30 Days)
- TSVT 726.2K
- SLRN 698.0K
- Earning Date
- TSVT 05-07-2025
- SLRN 05-16-2025
- Dividend Yield
- TSVT N/A
- SLRN N/A
- EPS Growth
- TSVT N/A
- SLRN N/A
- EPS
- TSVT N/A
- SLRN N/A
- Revenue
- TSVT $48,365,000.00
- SLRN N/A
- Revenue This Year
- TSVT $84.48
- SLRN $267.11
- Revenue Next Year
- TSVT $9.69
- SLRN N/A
- P/E Ratio
- TSVT N/A
- SLRN N/A
- Revenue Growth
- TSVT N/A
- SLRN N/A
- 52 Week Low
- TSVT $2.29
- SLRN $1.85
- 52 Week High
- TSVT $5.30
- SLRN $7.25
- Technical
- Relative Strength Index (RSI)
- TSVT 71.10
- SLRN 47.93
- Support Level
- TSVT $4.97
- SLRN $2.34
- Resistance Level
- TSVT $4.99
- SLRN $2.64
- Average True Range (ATR)
- TSVT 0.01
- SLRN 0.17
- MACD
- TSVT -0.04
- SLRN 0.02
- Stochastic Oscillator
- TSVT 50.00
- SLRN 48.70
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About SLRN ACELYRIN INC.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.